PE20121732A1 - SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS USEFUL INHIBITORS OF HSL IN THE TREATMENT OF DIABETES - Google Patents
SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS USEFUL INHIBITORS OF HSL IN THE TREATMENT OF DIABETESInfo
- Publication number
- PE20121732A1 PE20121732A1 PE2012000489A PE2012000489A PE20121732A1 PE 20121732 A1 PE20121732 A1 PE 20121732A1 PE 2012000489 A PE2012000489 A PE 2012000489A PE 2012000489 A PE2012000489 A PE 2012000489A PE 20121732 A1 PE20121732 A1 PE 20121732A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- hsl
- spiro
- diabetes
- treatment
- Prior art date
Links
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical class C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- -1 PHENYLALKYL Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000000019 Sterol Esterase Human genes 0.000 abstract 2
- 108010055297 Sterol Esterase Proteins 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- FIULGFJIHJJXMT-UHFFFAOYSA-N [C]1[N]C=CC=C1 Chemical class [C]1[N]C=CC=C1 FIULGFJIHJJXMT-UHFFFAOYSA-N 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE CICLOHEXANO ESPIRO-CONDENSADO DE FORMULA (I) DONDE R1 ES ALQUILO, FENILO, FENILALQUILO, PIRIDINILO, PIRAZOLILO, ENTRE OTROS; R2 ES H, ALQUILO, CICLOALQUILO, OXETANILALCOXILALQUILO, HIDROXIALQUILO, ENTRE OTROS; R3 ES R4-A- O ESTA AUSENTE SI Ca Y Cb SE UNEN POR UN DOBLE ENLACE, EN DONDE R4 ES H, ALQUILO, CICLOALQUILO, FENILO, ENTRE OTROS; A ES O, S, S(O), S(O)2, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (5a,8b)-8-HIDROXI-2-(4-TRIFLUOROMETOXI-FENIL)-2-AZA-ESPIRO[4.5]DECAN-1-ONA; (5a,8b)-2-(4-ETIL-FENIL)-1-OXO-2-AZA-ESPIRO[4.5]DEC-8-IL] ESTER DEL ACIDO (3-FLUORO-BENCIL)-CARBAMICO; (5a,8b)-8-HIDROXI-8-ISOPROPIL-2-[4-(2,2,2-TRIFLUORO-ETOXI)-FENIL]-2-AZA-ESPIRO[4.5]DECAN-1-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA LIPASA SENSIBLE A HORMONAS (HSL) SIENDO UTILES EN EL TRATAMIENTO DE DIABETES, SINDROME METABOLICO, OBESIDADREFERS TO COMPOUNDS DERIVED FROM SPIRO-CONDENSED CYCLOHEXANE OF FORMULA (I) WHERE R1 IS ALKYL, PHENYL, PHENYLALKYL, PYRIDINYL, PIRAZOLIL, AMONG OTHERS; R2 IS H, ALKYL, CYCLOALKYL, OXETANYLALCOXYLALKYL, HYDROXYALKYL, AMONG OTHERS; R3 IS R4-A- OR IS ABSENT IF Ca AND Cb ARE JOINED BY A DOUBLE LINK, WHERE R4 IS H, ALKYL, CYCLOALKYL, PHENYL, AMONG OTHERS; A IS O, S, S (O), S (O) 2, AMONG OTHERS. PREFERRED COMPOUNDS ARE: (5a, 8b) -8-HYDROXY-2- (4-TRIFLUOROMETOXY-PHENYL) -2-AZA-SPYRO [4.5] DECAN-1-ONA; (5a, 8b) -2- (4-ETHYL-PHENYL) -1-OXO-2-AZA-SPYRO [4.5] DEC-8-IL] (3-FLUORO-BENZYL) -CARBAMIC ACID ESTER; (5a, 8b) -8-HYDROXY-8-ISOPROPYL-2- [4- (2,2,2-TRIFLUORO-ETOXY) -PHENYL] -2-AZA-SPYRO [4.5] DECAN-1-ONA; AMONG OTHERS. IT ALSO REFERS TO A PREPARATION PROCEDURE AND A PHARMACEUTICAL COMPOSITION. SAID COMPOUNDS ARE INHIBITORS OF HORMONE SENSITIVE LIPASE (HSL), BEING USEFUL IN THE TREATMENT OF DIABETES, METABOLIC SYNDROME, OBESITY
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09173178 | 2009-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121732A1 true PE20121732A1 (en) | 2012-12-28 |
Family
ID=43093680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000489A PE20121732A1 (en) | 2009-10-15 | 2010-10-12 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS USEFUL INHIBITORS OF HSL IN THE TREATMENT OF DIABETES |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8440710B2 (en) |
| EP (1) | EP2488493B1 (en) |
| JP (1) | JP5749272B2 (en) |
| KR (1) | KR101576328B1 (en) |
| CN (1) | CN102858743B (en) |
| AR (1) | AR078619A1 (en) |
| AU (1) | AU2010305859A1 (en) |
| BR (1) | BR112012008962A2 (en) |
| CA (1) | CA2776457A1 (en) |
| CL (1) | CL2012000937A1 (en) |
| ES (1) | ES2538005T3 (en) |
| IL (1) | IL218958A0 (en) |
| IN (1) | IN2012DN03337A (en) |
| MX (1) | MX2012004311A (en) |
| PE (1) | PE20121732A1 (en) |
| PH (1) | PH12012500630A1 (en) |
| RU (1) | RU2607080C2 (en) |
| TW (1) | TW201118068A (en) |
| WO (1) | WO2011045292A1 (en) |
| ZA (1) | ZA201202613B (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2411395T1 (en) | 2009-03-23 | 2013-07-31 | Glenmark Pharmaceuticals S.A. | Furopyrimidinedione derivatives as trpa1 modulators |
| US8097634B2 (en) * | 2010-04-15 | 2012-01-17 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
| US8722721B2 (en) * | 2011-03-16 | 2014-05-13 | Hoffmann-La Roche Inc. | SEC-hydroxycyclohexyl derivatives |
| US8703807B2 (en) * | 2011-03-17 | 2014-04-22 | Hoffmann-La Roche Inc. | Azaspirodecanone compounds |
| US8809384B2 (en) | 2011-03-25 | 2014-08-19 | Hoffmann-La Roche Inc. | Azaspirodecanone compounds |
| CN103319395B (en) * | 2013-04-08 | 2014-09-24 | 武汉罗化科技有限公司 | A kind of industrial preparation method and product of 4-fluoroisatin |
| WO2015103756A1 (en) * | 2014-01-09 | 2015-07-16 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| UY36060A (en) | 2014-04-02 | 2015-10-30 | Bayer Pharma AG | AZOL COMPOUNDS REPLACED WITH AMIDA |
| KR102732404B1 (en) | 2017-11-01 | 2024-11-19 | 브리스톨-마이어스 스큅 컴퍼니 | Alkene compounds as farnesoid X receptor modulators |
| KR102732405B1 (en) | 2017-11-01 | 2024-11-20 | 브리스톨-마이어스 스큅 컴퍼니 | Alkene spirocyclic compounds as farnesoid X receptor modulators |
| CA3081424A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Spirocyclic compounds as farnesoid x receptor modulators |
| AR113820A1 (en) | 2017-11-01 | 2020-06-17 | Bristol Myers Squibb Co | BRIDGE BICYCLIC COMPOUNDS AS MODULATORS OF THE X FARNESOID RECEIVER |
| WO2019089664A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Multicyclic compounds as farnesoid x receptor modulators |
| CN109369354B (en) * | 2018-12-15 | 2021-07-09 | 浦拉司科技（上海）有限责任公司 | A kind of synthetic method of 4,4,4-trifluorobutanol |
| SG11202108794RA (en) | 2019-02-15 | 2021-09-29 | Bristol Myers Squibb Co | Substituted amide compounds useful as farnesoid x receptor modulators |
| KR102883856B1 (en) | 2019-02-15 | 2025-11-10 | 브리스톨-마이어스 스큅 컴퍼니 | Substituted amide compounds useful as farnesoid X receptor modulators |
| AR118050A1 (en) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | BICYCLIC COMPOUNDS REPLACED AS MODULATORS OF THE FARNESOID X RECEIVER |
| EP3924337A1 (en) | 2019-02-15 | 2021-12-22 | Bristol-Myers Squibb Company | Substituted bicyclic compounds as farnesoid x receptor modulators |
| CN117567380B (en) * | 2023-11-17 | 2025-10-17 | 广东药科大学附属第一医院 | Triazole HSL inhibitor, preparation method and application thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10247680B4 (en) * | 2002-10-12 | 2005-09-01 | Aventis Pharma Deutschland Gmbh | New bicyclic inhibitors of the hormone sensitive lipase |
| US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| CA2549510A1 (en) | 2003-12-16 | 2005-07-07 | Pfizer Products Inc. | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors |
| FR2870538B1 (en) * | 2004-05-19 | 2006-07-14 | Servier Lab | NOVEL DERIVATIVES OF PYRROLIDINES AND THIAZOLIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| US20070208001A1 (en) | 2006-03-03 | 2007-09-06 | Jincong Zhuo | Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
| PL2021337T3 (en) * | 2006-04-25 | 2010-06-30 | Lilly Co Eli | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| AU2007244861B2 (en) | 2006-04-25 | 2012-03-15 | Eli Lilly And Company | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| GB0705656D0 (en) | 2007-03-23 | 2007-05-02 | Addex Pharmaceuticals Sa | Novel compounds E1 |
-
2010
- 2010-10-08 US US12/900,621 patent/US8440710B2/en not_active Expired - Fee Related
- 2010-10-12 IN IN3337DEN2012 patent/IN2012DN03337A/en unknown
- 2010-10-12 MX MX2012004311A patent/MX2012004311A/en active IP Right Grant
- 2010-10-12 RU RU2012119706A patent/RU2607080C2/en not_active IP Right Cessation
- 2010-10-12 BR BR112012008962A patent/BR112012008962A2/en not_active IP Right Cessation
- 2010-10-12 AU AU2010305859A patent/AU2010305859A1/en not_active Abandoned
- 2010-10-12 KR KR1020127012343A patent/KR101576328B1/en not_active Expired - Fee Related
- 2010-10-12 PH PH1/2012/500630A patent/PH12012500630A1/en unknown
- 2010-10-12 TW TW099134747A patent/TW201118068A/en unknown
- 2010-10-12 CA CA2776457A patent/CA2776457A1/en not_active Abandoned
- 2010-10-12 EP EP10770764.8A patent/EP2488493B1/en not_active Not-in-force
- 2010-10-12 JP JP2012533604A patent/JP5749272B2/en not_active Expired - Fee Related
- 2010-10-12 CN CN201080046313.0A patent/CN102858743B/en not_active Expired - Fee Related
- 2010-10-12 WO PCT/EP2010/065232 patent/WO2011045292A1/en not_active Ceased
- 2010-10-12 PE PE2012000489A patent/PE20121732A1/en not_active Application Discontinuation
- 2010-10-12 ES ES10770764.8T patent/ES2538005T3/en active Active
- 2010-10-13 AR ARP100103732A patent/AR078619A1/en unknown
-
2012
- 2012-03-29 IL IL218958A patent/IL218958A0/en unknown
- 2012-04-11 ZA ZA2012/02613A patent/ZA201202613B/en unknown
- 2012-04-13 CL CL2012000937A patent/CL2012000937A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12012500630A1 (en) | 2012-10-22 |
| HK1179957A1 (en) | 2013-10-11 |
| KR20120074304A (en) | 2012-07-05 |
| CL2012000937A1 (en) | 2012-09-14 |
| US8440710B2 (en) | 2013-05-14 |
| CN102858743A (en) | 2013-01-02 |
| CN102858743B (en) | 2015-06-10 |
| US20110092512A1 (en) | 2011-04-21 |
| RU2012119706A (en) | 2013-11-20 |
| BR112012008962A2 (en) | 2019-09-24 |
| ZA201202613B (en) | 2013-01-30 |
| CA2776457A1 (en) | 2011-04-21 |
| KR101576328B1 (en) | 2015-12-10 |
| AR078619A1 (en) | 2011-11-23 |
| EP2488493A1 (en) | 2012-08-22 |
| MX2012004311A (en) | 2012-04-30 |
| RU2607080C2 (en) | 2017-01-10 |
| JP2013507421A (en) | 2013-03-04 |
| ES2538005T3 (en) | 2015-06-16 |
| IN2012DN03337A (en) | 2015-10-23 |
| EP2488493B1 (en) | 2015-04-15 |
| WO2011045292A1 (en) | 2011-04-21 |
| TW201118068A (en) | 2011-06-01 |
| JP5749272B2 (en) | 2015-07-15 |
| AU2010305859A1 (en) | 2012-06-07 |
| IL218958A0 (en) | 2012-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121732A1 (en) | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS USEFUL INHIBITORS OF HSL IN THE TREATMENT OF DIABETES | |
| UY29575A1 (en) | POLYMODIC FORMS OF ETHYL ETHYL ESTER 3 - ((2 - ((4- (HEXILOXICARBONILAMINO - IMINO-METIL) -PENYLAMINO) -METIL) -1-METHYL-BENCIMIDAZOL-5-CARBONIL) -PIRIDIN-2-IL - -AMINO) -PROPIÓNICO | |
| PE20110136A1 (en) | ORGANIC COMPOUNDS | |
| PE20091002A1 (en) | DIPEPTIDED ANALOGS AS INHIBITORS OF THE COAGULATION FACTOR | |
| UY28493A1 (en) | METHYLOSULPHONATE OF ETHYL ETHYL ESTER 3 - ((2 - ((4- (HEXILOXICARBONILAMINO-IMINO-METTIL) -PENYLAMINO) -METIL) -1-METHYL-1H-BENCIMIDAZOL-5-CARBONIL) -PIRIDIN-2-IL-AMINO ) -PROPIONIC AND ITS USE AS A MEDICINAL PRODUCT. | |
| CL2008000422A1 (en) | The compound 4- [4- (2-adamantylcarbamoyl) -5-tert-butylpyrazol-1-yl] -benzoic acid; pharmaceutical composition; its use as an inhibitor of 11bhsd1, useful in the treatment of type 2 diabetes and obesity. | |
| PE20142019A1 (en) | NEW DERIVATIVES OF INDANYLOXIDIHIDROBENZOFURANILACETICOS ACIDS AND THEIR USES AS AGONISTS OF THE GPR40 RECEPTOR | |
| NZ601121A (en) | 5-alkynyl-pyrimidines | |
| NZ716420A (en) | Fused heterocyclic compounds as sodium channel modulators | |
| PE20141682A1 (en) | (4-PHENYLIMIDAZOLE-2-IL) ETHYLAMINE DERIVATIVES USEFUL AS SODIUM CHANNEL MODULATORS | |
| PE20120690A1 (en) | DERIVATIVES OF 5-FLUOROPYRIMIDINONE | |
| NO20091548L (en) | Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors of diabetes | |
| TN2012000125A1 (en) | Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors | |
| EA201101671A1 (en) | SUBSTITUTED DERIVATIVES OF AMINOPROPIONIC ACID AS NEPRILISIN INHIBITORS | |
| EA201390198A1 (en) | Heterocyclic Compound | |
| PE20090547A1 (en) | PIRAZINONE DERIVATIVES AS p38 KINASE INHIBITORS | |
| PE20091828A1 (en) | CONDENSED CYCLOPENTANOCARBOXYLIC ACID DERIVATIVES REPLACED WITH ACILAMINE AS EDG-2 INHIBITORS | |
| PE20120585A1 (en) | CRYSTALLINE FORM OF DIHYDROGEN PHOSPHATE R) -3- (4- (2- (2-METHYLTETRAZOLE-5-IL) PYRIDIN-5-IL) -3-FLUOROFENSIL) -5-HYDROXIMETHYL OXAZOLIDIN-2-ONA | |
| MX339252B (en) | Pyrrolidine or thiazolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in treating metabolic disordersas as agonists of g- protein coupled receptor 43 (gpr43). | |
| MX2010008583A (en) | Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid. | |
| WO2012161518A3 (en) | Novel thiourea derivatives as activators of rorα and pharmaceutical composition containing same | |
| MX2011012199A (en) | Benzoxazolone derivatives as aldosterone symthase inhibitors. | |
| EA201390643A1 (en) | CRYSTAL FORMS OF HYDROCHLORIDE (4A-R, 9A-S) -1- (1H-BENZOIMIDAZOLE-5-CARBONYL-2,3,4,4A, 9,9A-HEXAHYDRO-1H-INDENO [2,1-B] PYRIDIN- 6-CARBONITRILE AND THEIR APPLICATION AS HSD 1 INHIBITORS | |
| ECSP11010849A (en) | N- (2-AMINOPHENYL) -4- [N- (PIRIDIN-3-IL) METOXICARBONYLAMINE-METHYL] POLYMORPH B BENZAMIDE (MS-275) | |
| WO2011047055A3 (en) | Novel mek inhibitors, useful in the treatment of diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |